Skip to content

Feasibility of Tracheobronchial Reconstruction Using Bioengineered Aortic Matrices

Feasibility of Tracheobronchial Reconstruction Using Bioengineered Aortic Matrices

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04850742
Enrollment
5
Registered
2021-04-20
Start date
2019-01-01
Completion date
2024-03-31
Last updated
2021-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Disease, Lung Cancer, Trachea Diseases, Tracheal Stenosis, Tuberculosis; Tracheitis

Keywords

tracheal reconstruction, bronchial reconstruction, cryopreserved aorta

Brief summary

We used a segment of cryopreserved aorta as a graft for reconstruction for long segment tracheobronchial lesion in human.

Interventions

After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with advanced benign or malignant lesions involving trachea or bronchi, and has failed conventional treatment. * Patients with proximal pulmonary tumors that require surgical resection and has involved proximal airways which is indicated for a pneumonectomy, sleeve lobectomy, or carina resection.

Exclusion criteria

* Less than 20-year-old * Unable to obtain informed consent. * Pulmonary tumors that can be treated with standard lobectomy. * Unresectable locally advanced malignant tumors * Malignant tumors with contralateral lymph nodes involvement. * Malignant tumors with distal metastases; except for simple resectable brain metastasis. * Tracheal lesions which can be treated with standard resection and direct anastomosis. * Allergic to iodine * Unable to tolerate standard lobectomy * Has human immunodeficiency virus infection * Tracheal stenosis at proximal 2 cm on upper trachea

Design outcomes

Primary

MeasureTime frameDescription
90-day mortality90 daysThe rate of death at 90 days.

Secondary

MeasureTime frameDescription
90-day morbidity90 daysThe occurrence of complication including 1) anastomotic leakage, 2) pneumonia, 3) difficult weaning, 4) airway obstruction by granulation tissue, 5) stenosis.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026